Respiratory syncytial virus disease: update on treatment and prevention

References

• Morris JA, Blant RE Jr, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc. Soc. Exp. Bio. Med.92, 544–550 (1956).
   PubMed Web of Science ®Google Scholar
• Chanock R, Finberg L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza (CCA). II. Epidemiologic aspects of infection in infants and young children. Am. J. Hyg.66, 291–300 (1957).
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, Iwane MK et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med.360, 588–598 (2009).
   PubMed Web of Science ®Google Scholar
• Shay DK, Holman RC, Newman RD et al. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA282, 1440–1446 (1999).
   PubMed Web of Science ®Google Scholar
• Howard TS, Hoffman LH, Stang PE, Simoes EA. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. J. Pediatr.137, 227–232 (2000).
   PubMed Web of Science ®Google Scholar
• Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J. Pediatr.14, S127–S132 (2003).
   Google Scholar
• Boyce TG, Mellen BG, Mitchel EF Jr et al. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J. Pediatr.137, 865–870 (2000).
   PubMed Web of Science ®Google Scholar
• Law BJ, MacDonald NE, Langley JM et al. Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: what are we trying to prevent?. J. Paediatr. Child Health3(6), 402–404 (1998).
   PubMedGoogle Scholar
• Falsey AR, Hennessey PA, Formica MA et al. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med.352, 1749–1759 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA289, 227–229 (2003).
   PubMed Web of Science ®Google Scholar
• Sigurs N, Gustafsson PM, Bjarnason R et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am. J. Respir. Crit. Care Med.171, 137–141 (2005).
   PubMed Web of Science ®Google Scholar
• Stein RT, Sherril D, Morgan WJ et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet354, 541–545 (1999).
   PubMed Web of Science ®Google Scholar
• Taussig LM, Wright AL, Holberg CJ et al. Tuscon children’s respiratory study 1980 to present. J. Allergy Clin. Immunol.111, 661–675 (2003).
   PubMed Web of Science ®Google Scholar
• Collins PL, Channock RM, Murphy BR. Respiratory syncytial virus. In: Field’s Virology. Knipe DM, Howley PM et al. (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA, 1443–1485 (2001).
   Google Scholar
• Hall CB, Walsh EE, Schnabel KC et al. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J. Infect. Dis.162, 1283–1290 (1990).
   PubMed Web of Science ®Google Scholar
• Subcommittee on diagnosis and management of bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics118, 1774–1793 (2006).
   PubMed Web of Science ®Google Scholar
• Gadomski AM, Bhasale AL. Bronchodilators for bronchiolitis. Cochrane Database Syst. Rev.3, CD001266 (2009).
   Google Scholar
• Flores G, Horwitz RI. Efficacy of b2 agonists in bronchiolitis: a reappraisal and metaanalysis. Pediatrics100, 233–239 (1997).
   PubMed Web of Science ®Google Scholar
• Patel H, Gouin S, Platt RW. Randomized, double-blind, placebo-controlled trial of oral albuterol in infants with mild-to-moderate acute viral bronchiolits. J. Pediatr.142, 509–514 (2003).
   PubMed Web of Science ®Google Scholar
• Schuh S, Canny G, Reismann JJ et al. Nebulized albuterol in acute bronchiolitis. J. Pediatr.117, 633–637 (1990).
   PubMed Web of Science ®Google Scholar
• Gadomski AM, Lichenstein R, Horton L et al. Efficacy of albuterol in the management of bronchiolitis. Pediatrics93, 907–912 (1994).
   PubMed Web of Science ®Google Scholar
• Hartling L, Wiebe N, Russell K et al. Epinephrine for bronchiolitis. Cochrane Database Syst. Rev.1, CD003123 (2004).
   Google Scholar
• Wainwright C, Altamirano L, Cheney M et al. A multicenter, randomized, double‑blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis. N. Engl. J. Med.349, 27–35 (2003).
   PubMed Web of Science ®Google Scholar
• Menon K, Sutcliffe T, Klassen TP. A randomized trial comparing the efficacy of epinephrine with salbutamol in the treatment of acute bronchiolits. J. Pediatr.126, 1004–1007 (1995).
   PubMed Web of Science ®Google Scholar
• Corneli HM, Zorc JJ, Majahan P et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N. Engl. J. Med.357, 331–339 (2007).
   PubMed Web of Science ®Google Scholar
• Patel H, Platt R, Lozano JM, Wang EEL. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Dtabase Syst. Rev.4, 1–63 (2004).
   Google Scholar
• Amirav I, Luder AS, Kruger N et al. A double-blind, placebo-controlled, randomized trial of montelelukast for acute bronchiolitis. Pediatrics122, e1249–e1255 (2008).
   PubMed Web of Science ®Google Scholar
• Bisgaard H. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am. J. Respir. Crit. Care Med.167, 290–296 (2003).
   PubMed Web of Science ®Google Scholar
• Ventre K, Randolph A. Ribavirin for respiratory syncytial virus infection of the LRTI in infants and young children. Cochrane Database Syst. Rev.4, CD000181 (2004).
   Google Scholar
• McColl MD, Corser RB, Bremner J, Chopra R. Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin. Bone Marrow Transplant.21, 423–425 (1998).
   PubMed Web of Science ®Google Scholar
• Glezen WP, Paredes A, Allison JE et al. Risk of respiratorysyncytial virus infection for infants from low-income families in relationshipto age, sex, ethnic group, and maternal antibody level. J. Pediatr.98, 708–715 (1981).
   PubMed Web of Science ®Google Scholar
• The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics102, 531–537 (1998).
   PubMed Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner HC et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr.143, 532–540 (2003).
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Respiratory syncytial virus. In: Red Book: 2009 Report of the Committee on Infectious Diseases. 28th Edition. Pickering LK, Baker CJ, Kimberlin DW, Long SS (Eds). American Academy of Pediatrics, Elk Grove Village, IL, USA, 560–569 (2009).
   Google Scholar
• American Academy of Pediatrics. Respiratory syncytial virus. In: Red Book: 2006 Report of the Committee on Infectious Diseases. 27th Edition. Pickering LK, Baker CJ, Long SS, McMillan JA (Eds). American Academy of Pediatrics, Elk Grove Village, IL, USA, 560–566 (2006).
   Google Scholar
• Krilov LR, Weiner LB, Yogev R et al. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost and evidence-based medicine. Pediatrics124, 1682–1684 (2009).
   PubMed Web of Science ®Google Scholar
• Krilov LR, Palazzi DL, Fernandes AW et al. Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States. Value Health13, 77–86 (2010).
   PubMed Web of Science ®Google Scholar
• Simoes EAF, Groothuis JR, Carbonell‑Estrany X et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent wheezing. J. Pediatr.151, 34–42 (2007).
   PubMed Web of Science ®Google Scholar
• Malley R, DeVincenzo JP, Ramilo O et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis.178, 1555–1561 (1998).
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Johnson S et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol.368, 652–665 (2007).
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Simoes EAF, Dagan R et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics125, e35–e51 (2010).
   PubMed Web of Science ®Google Scholar
• Lagos R, DeViencenzo JP, Munoz A et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody when administered to RSV-infected children. Pediatr. Infect. Dis. J.28, 835–837 (2009).
   PubMed Web of Science ®Google Scholar
• Olszewska W, Openshaw P. Emerging drugs for respiratory syncytial virus infection. Expert Emerg. Drugs142, 207–217 (2009).
   Google Scholar
• Empey KM, Peebles RS Jr, Kolls JK. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin. Infect. Dis.50, 1258–1264 (2010).
   PubMed Web of Science ®Google Scholar
• Power UF. Respiratory syncytial virus (RSV) vaccines – two steps back for one leap forward. J. Clin. Virol.41, 38–44 (2008).
   PubMed Web of Science ®Google Scholar
• Janssen R, Bont L, Siezen CL et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominately associated innate immune genes. J. Infect. Dis.196, 826–834 (2007).
   PubMed Web of Science ®Google Scholar